Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chris Rallis Insider Profile
4 Followers
Chris Rallis, Director at Fennec Pharmaceuticals, holds 46.46K shares in Fennec Pharmaceuticals (Ticker: FENC), holds ― shares in Tenax Therapeutics (Ticker: TENX).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-33.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Chris Rallis holds in companies
Most Profitable Insider Trade
The most profitable trade made by Chris Rallis
Chris Rallis's Trading History
Fennec Pharmaceuticals
Jul 08, 2024
Director
Uninformative Buy
1.73K
$305.22K
Tenax Therapeutics
Aug 22, 2016
Director
Informative Buy
25.00K
―
List of latest transactions for each holding click on a transaction to see Chris Rallis's performance on stock
You May Also Like
Chris Rallis insider profile FAQ
What is the percentage of profitable transactions made by Chris Rallis?
The percentage of profitable transactions made by Chris Rallis is 50%.
What is the average return per transaction made by Chris Rallis?
The average return per transaction made by Chris Rallis is -33.60%.
What stocks does Chris Rallis hold?
Chris Rallis holds: FENC, TENX stocks.
What was Chris Rallis’s latest transaction?
Chris Rallis latest transaction was an Uninformative Buy of $1.73K.
What was Chris Rallis's most profitable transaction?
Chris Rallis’s most profitable transaction was an Informative Sell of FENC stock on August 18, 2023. The return on the trade was 18.30%.
What is Chris Rallis's role in Fennec Pharmaceuticals?
Chris Rallis's role in Fennec Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.